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Although adjuvant chemotherapy (AC) has been established as a standard of treatment for
advanced rectal cancer, there is no guideline regarding the timing of AC initiation. In this
study, we aimed to evaluate the oncologic outcome of early AC initiation and clarify the ideal
time to AC among rectal cancer patients receiving preoperative chemo-radiotherapy
(preCRT).
Methods
The medical records of 719 patients who underwent curative resection followed by AC for
rectal cancer were analyzed retrospectively. Data distributions were compared according to
the calculated cut-off for AC initiation, survival results, and chemotherapy-induced toxicity.
Additionally, patients were divided into two groups according to preCRT status and com-
pared with respect to differences in the optimal time to AC.
Results
Overall, a cut-off time point of 20 days after surgery for AC initiation was identified as the
optimal interval; this yielded a significant difference in disease-free survival but no significant
difference in AC toxicity. In the cut-off analysis of patients treated without preCRT, 19 days
was identified as the optimal time to AC. However, for patients treated with preCRT, no sig-
nificant value affected the survival outcome.
Conclusions
Earlier initiation of AC (within approximately 3 weeks) was associated with better oncological
outcomes among patients with rectal cancer. Additionally, the optimal timing of AC was
unclear among patients who received preCRT; this might be attributable to an undetermined
role of AC after preCRT or the effects of complications such as anastomotic leakage.
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Introduction
Adjuvant chemotherapy (AC) has been established as a current standard of treatment for colo-
rectal cancer (CRC), although surgical resection is the primary treatment modality. Multiple
trials of AC after curative resection for CRC have consistently demonstrated improvements in
survival, and current guidelines recommend AC for patients with advanced CRC.[1–3] How-
ever, no guideline has been set regarding the timely initiation of AC, although the routine clin-
ical assumption suggests that AC should be initiated as soon as possible.[2, 4, 5] A review of
the literature indicates that early initiation of AC is most often defined as initiation within 8
weeks after surgery and has been shown to improve prognosis.[6–9] Therefore, a consensus
has been reached regarding AC initiation within 8 weeks after curative surgery for CRC.[10–
16] In recent decades, the application of enhanced recovery after surgery (ERAS) protocols
and development of minimally invasive surgery (MIS) techniques have enabled earlier initia-
tion of postoperative chemotherapy. ERAS protocols and MIS techniques such as laparoscopic
surgery yield shortened hospital stays and more rapid postoperative recovery relative to con-
ventional practices, and subsequently allow earlier initiation of AC.[17–27] Whether AC initi-
ation earlier than 8 weeks can provide further improvements, however, is yet to be established.
In contrast to colon cancer, current guidelines recommend preoperative chemo-radiother-
apy (preCRT) for patients with advanced rectal cancer.[3, 5] Previous studies evaluating the
optimal timing of AC specifically in rectal cancer suggested a period of 8 weeks after surgery,
similar to colon cancer; however, preCRT was not considered.[28, 29] Currently, there is
insufficient evidence to support to AC initiation within 8 weeks after surgery for patients who
received preCRT.
This study aimed to evaluate the oncologic outcomes of early AC initiation and clarify the
ideal time to AC among patients with rectal cancer. We also sought to investigate the differ-
ence in the optimal time to AC initiation between patients treated with and without preCRT.
Materials and methods
The medical records of consecutive patients who underwent curative resection and received
AC for the treatment of rectal cancer from January 2006 to December 2012 were reviewed ret-
rospectively. The study was reviewed and approved by the Severance Hospital Institutional
Review Board. (IRB No. 4-2016-1007) A waiver of informed consent was approved by the
Institutional Review Board given the retrospective nature of the study.
Inclusion and exclusion criteria
The eligibility criteria were a histologically confirmed rectal adenocarcinoma located within 15
cm from the anal verge, and major rectal resection with curative intent followed by AC.
Patients who underwent R2 resection for macroscopic residual disease or non-resectional pro-
cedures for rectal cancer and those who did not receive AC were excluded.
Treatment protocol
Patients treated without preoperative chemo-radiation therapy. Standard total mesor-
ectal excision procedures were performed. AC was performed for patients with pathologic
stage II and more by medical oncologists using individualized initiation timing plans that con-
sidered patients’ postoperative recovery. AC regimens were categorized and analyzed accord-
ing to base chemotherapeutic agents, rather than according to delivery methods. Selected
patients received postoperative radiotherapy with respect to the tumor location, tumor inva-
sion depth, perirectal lymph node metastasis, circumferential resection margin, comorbidities,
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and postoperative performance scale. All surgical patients were followed up at 3- or 6-month
intervals for the first 5 years and annually thereafter.
Patients with preoperative chemo-radiation therapy. PreCRT was performed as long-
course radiotherapy (50.4 Gy radiation/28 fractions/6 weeks) with 2 concurrent cycles of
5-fluorouracil (5-FU) infusion or oral capecitabine. Definite surgery was performed 4–8 weeks
after the termination of CRT. AC was performed for patients with initial clinical stage II and
more at diagnosis. Surgical maneuvers, AC, and follow-up were identical to those described
for patients treated without preCRT. Postoperative radiotherapy was not indicated for these
patients.
Variables and outcomes
A survival analysis was performed to identify the associations between the time to AC and
oncologic outcomes; the following variables were included in the analysis: age, sex, American
Society of Anesthesiologists (ASA) grade, preoperative carcinoembryonic antigen (CEA) level,
preCRT, surgical method (open surgery or MIS), pathological stage, histologic grade, lympho-
vascular invasion, anastomotic leakage, duration of hospital stay after surgery, time to AC, and
chemotherapy regimen. MIS included laparoscopic and robotic surgery. Pathologic stage was
based on the seventh edition of the American Joint Commission on Cancer tumor-node-
metastasis (TNM) system and included both pTNM for patients treated without preCRT and
ypTNM for patients treated with preCRT.[30] Anastomotic leakage was defined as the break-
down of a colorectal anastomosis along with infected fluid collection in the pelvic cavity; this
condition was diagnosed by using computed tomography findings or clinical symptoms and
signs, including a change in drainage color and/or fever with peritonitis. Time to AC was
defined as the number of days between curative rectal cancer surgery and the initial chemo-
therapeutic agent administration. We adopted disease-free survival (DFS) and overall survival
(OS) as oncologic outcomes. Patients who experienced grade�3 chemotherapy-induced com-
plications and required chemotherapy dose reductions or discontinuation because of toxicity
were analyzed to identify the safety of and tolerance to early AC initiation. In this analysis,
complication grades was based on the Common Terminology Criteria for Adverse Events
(CTCAE), version 4.0.[31] To investigate differences in the optimal time of AC initiation
between patients treated with and without preCRT, we categorized patients into two groups
based on preCRT status and analyzed them, respectively.
Statistical analysis
All statistical analyses were performed using SPSS Statistics (version 20.0.; IBM Corp.,
Armonk, NY, USA), except calculations of the time to AC initiation cut-off point. Descriptive
results are presented as medians with interquartile ranges (quartile [Q]1–Q3) for continuous
outcomes and as frequencies and percentages for categorical outcomes. Differences in survival
between patients who initiated AC within and beyond the cut-off point were estimated using
the Kaplan–Meier method and compared using the log-rank test. Factors associated with DFS
and OS were analyzed using a Cox proportional hazards regression analysis. In this analysis,
the continuous variables of CEA and time to AC were dichotomized based on the normal limi-
tation of 5 ng/ml and the calculated cut-off point, respectively. The optimal cut-offs for the
time to AC initiation were assessed via maximally selected log-rank statistics, using the R Max-
stat package (version 3.2.2.; R Foundation for Statistical Computing, Vienna, Austria).[32] All
variables in the risk set were assessed as putative prognostic factors for DFS and OS in an
unadjusted Cox regression. Variables with a P value of<0.10 in the unadjusted Cox regression
were selected for the risk-adjusted Cox regression. A binary logistic regression model was used
Early adjuvant chemotherapy in rectal cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0228060 January 31, 2020 3 / 12
to identify the risks of chemotherapy-induced complications and tolerance to chemotherapy




A total of 977 patients were included in this analysis and were followed up for a median of 52.0
months (range, 32.0–70.0 months). The median interval between surgery and AC was 27.0
days (range, 21.0–33.0 days). Among the total patients, 872 (89.3%) and 251 (25.7%) received
AC within 6 and 3 weeks, respectively (Fig 1). The median age of the patients was 60.0 years
(range, 52.0–67.0 years), and more men (63.9%) than women (36.1%) were included (Table 1).
Among all patients, 258 (26.4%) underwent preCRT, whereas 719 (73.6%) did not. MIS was
predominant (62.7%), compared to open surgery (37.3%). Most patients (83.2%) had patho-
logic stage II or III disease. Nine patients (0.9%) achieved a pathologic complete response
(pCR, yp0) after preCRT, yielding a pCR rate of 3.5% (9/258 patients treated with preCRT).
There were 111 patients (11.4%) presented with distant metastasis and underwent curative sur-
gery. Sixty-eight patients (7.0%) experienced anastomotic leakage after surgery, and all such
complications occurred before AC initiation. The median hospital stay duration after surgery
was 10.0 days (range, 8.0–14.0 days). Regarding chemotherapeutic regimens, 5-FU only che-
motherapy was most frequently used for AC (675 patients, 69.1%), followed by 5-FU plus
Fig 1. Distribution of the time to adjuvant chemotherapy in 977 patients.
https://doi.org/10.1371/journal.pone.0228060.g001
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Table 1. Characteristics of all patients.
Demographics (N = 977)









�5 ng/ml 640 (65.5%)






Open surgery 364 (37.3%)
Minimally invasive surgery 613 (62.7%)
















Postoperative hospital stay 10.0 (8.0–14.0)
Time to adjuvant chemotherapy 27.0 (21.0–33.0)
Regimen for adjuvant chemotherapy
Ÿ5-FU only 675 (69.1%)
5-FU plus oxaliplatin 208 (21.3%)
Capecitabine only 77 (7.9%)
5-FU plus Irinotecan 17 (1.7%)
Data are presented as medians (interquartile range, Q1-Q3), or n (%).
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oxaliplatin chemotherapy (208 patients, 21.3%). Capecitabine only and 5-FU plus irinotecan
were used in 77 (7.9%) and 17 patients (1.7%), respectively.
Analysis for overall patients
On calculation of the cut-off point of AC initiation among all the patients, 20 days after surgery
was identified as the optimal interval with regard to DFS. A significant difference was observed
when DFS was compared between patients who initiated AC within and beyond 20 days (Fig
2a). Patients who initiated chemotherapy within 20 days had a better 5-year DFS, compared to
those who initiated chemotherapy beyond 20 days (75.8% vs. 64.8%, p = 0.014). However, the
groups did not differ significantly in terms of OS (81.0% vs. 81.1%, respectively, p = 0.498). In
the multivariate analysis of DFS, patients who received AC beyond 20 days had a significant
hazard ratio (HR) of 1.5 when compared to patients who received AC within 20 days (95%
confidence interval [CI]: 1.1–2.1; p = 0.01) after adjusting for potential confounders (Table 2).
Among all patients, 218 (22.3%) developed grade 3 or 4 chemotherapy-induced complica-
tions such as stomatitis, neutropenia, and diarrhea. A total of 226 patients (23.1%) required
dose reduction, and the rate of chemotherapy discontinuation because of toxicity was 5.5%
(n = 54). An analysis of safety and tolerance to early AC found no difference in the incidence
of grade�3 chemotherapy-induced complications between the patients who initiated AC
within and beyond 20 days after surgery (Table 3). Those in the latter group exhibited poorer
tolerance to chemotherapeutic toxicity (odds ratio [OR] = 1.5; 95% CI: 1.0–2.12; p = 0.03).
After adjusting for potential confounders, the result was not significant but demonstrated a
trend towards increased risk. (OR = 1.4; 95% CI: 0.99–2.1; p = 0.06).
Subgroup analysis of patients according to preoperative chemo-
radiotherapy status
A cut-off point analysis for DFS among the patients treated without preCRT (median time to
AC = 26.0 days [range, 21.0–32.0 days]) identified 19 days as the optimal time to AC. Patients
who initiated AC within 19 days had a better DFS, compared to those who initiated AC
beyond 19 days (p = 0.01; Fig 2b). In a multivariate analysis for DFS, patients who initiated AC
beyond 19 days had a significant HR of 1.7, compared to those who initiated AC within 19
days (95% CI: 1.1–2.5; p = 0.01) after adjusting for potential confounders. Additionally, post-
operative radiotherapy, which was performed in 328 (45.6%) of the 719 patients treated with-
out preCRT, was not relevant to DFS and OS in this analysis. Among patients treated with
preCRT (median time to AC = 31.0 days [range, 25.8–37.3 days]), no significant value affected
Fig 2. Kaplan–Meier curves for disease-free survival among all the patients (a), patients treated without
preoperative chemo-radiotherapy (b), and patients treated with preoperative chemo-radiotherapy (c).
Comparisons of patients who initiated adjuvant chemotherapy within the cut-off point (blue line) and beyond the cut-
off point (green line).
https://doi.org/10.1371/journal.pone.0228060.g002
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the survival outcome. Patients who underwent AC within 56 days after surgery tended to have
a better DFS, compared to other patients (p = 0.156; Fig 2c). No significant difference in OS
was observed with respect to the cut-off point in either subgroup.
Factors preventing early adjuvant chemotherapy
The major factors that prevented early AC (i.e., before the defined cut-off point) were general
weakness (objective patient condition deemed inadequate for AC according to clinicians’ judg-
ment), poor compliance (patients’ own refusal despite clinicians’ recommendation), and anas-
tomosis-related complications. (Table 4) The influencing factors differed with respect to
Table 2. Cox regression disease-free survival in all patients.
Variables Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age 1.000 (0.989–1.011) 0.940
Sex (female) 0.736 (0.574–0.942) 0.015 0.667 (0.518–0.858) 0.002
†ASA 1.113 (0.907–1.365) 0.306
Surgical method 0.004 0.314
Open surgery 1 1
Minimally invasive surgery 0.717 (0.570–0.902) 0.883 (0.692–1.126)
‡CEA (>5 ng/ml) 1.862 (1.478–2.347) <0.001 1.394 (1.098–1.771) 0.006
Pathologic stage 2.647 (2.233–3.137) <0.001 2.183 (1.768–2.696) <0.001
Histologic grade 1.755 (1.322–2.331) <0.001 1.459 (1.089–1.939) 0.011
Lymphovascular invasion (present) 2.017 (1.604–2.536) <0.001 1.329 (1.042–1.694) 0.022
Anastomotic leakage (present) 1.382 (0.910–2.099) 0.129
Time to adjuvant chemotherapy (>20 days) 1.471 (1.077–2.010) 0.015 1.520 (1.102–2.097) 0.011
Postoperative hospital stay 1.024 (1.012–1.037) <0.001 1.016 (1.003–1.029) 0.015
Chemotherapy regimen <0.001 0.647
Ÿ5-FU only 1 1
5-FU plus oxaliplatin 1.001 (0.623–1.607) 1.201 (0.745–1.935)
Capecitabine only 2.185 (1.700–2.809) 1.130 (0.842–1.516)
5-FU plus Irinotecan 4.766 (2.708–8.388) 1.390 (0.728–2.635)




Table 3. Odds ratios for patients who initiated chemotherapy beyond 20 days relative to within 20 days after
surgery.
Odds ratio (95% confidence interval) P
Chemotherapy-induced complication grade�3
Not adjusted 0.921 (0.635–1.335) 0.664
Adjusted for age, †ASA, and chemotherapeutic regimen 0.895 (0.611–1.312) 0.571
Dose reduction or discontinuation of chemotherapy due to toxicity
Not adjusted 1.504 (1.037–2.180) 0.031
Adjusted for age, ASA, and chemotherapeutic regimen 1.444 (0.987–2.112) 0.058
†ASA, American Society of Anesthesiologists.
https://doi.org/10.1371/journal.pone.0228060.t003
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treatment strategy (i.e., preCRT status). Among patients treated without preCRT, 576 under-
went AC beyond the cut-off point of 19 days after surgery. Among them, 237 (41.1%) and 223
patients (38.7%) exhibited general weakness and poor compliance, respectively, two of the
leading causes known to interfere with early AC among patients treated without preCRT.
Anastomosis-related complications, particularly anastomotic leakage, were observed in 56
patients (9.7%). Among those treated with preCRT, 17 underwent AC beyond the cut-off
point of 56 days after surgery. Ten of these patients (47.1%) presented with anastomosis-
related complications, the leading cause of delayed AC. Among patients treated with preCRT,
surgical complications such as anastomotic leakage were a major reason for delaying AC, in
contrast to patients treated without preCRT.
Discussion
Without a guideline for timely AC initiation, the routine clinical assumption is that AC should
be initiated as soon as possible.[2, 4, 5] Theoretically, the early initiation of AC suggests a cer-
tain benefit. The Goldie–Coldman mathematical model predicts the probability of mutations
that lead to increased drug resistance over time and depend on the mutation rate and tumor
size.[33] Animal model studies suggest that surgery might increase the number of circulating
tumor cells and potentiate the growth of metastatic deposits in response to the enhanced pro-
duction of oncogenic growth factors after surgery.[34–39] This kinetic model and research
results from preclinical tumor growth studies support the advantage of early AC initiation
with respect to the eradication of micrometastatic deposits. Accordingly, the initiation of AC
within 8 weeks after surgery has been traditionally recommended.[10–16]
Nowadays, the time to AC has shrunk following the application of ERAS protocols and
expansion of MIS techniques. In our institution, the application of a “critical pathway” and
expansion of MIS enabled the early initiation of AC; for example, 89.3% of patients in the pres-
ent study received AC within 6 weeks. Such circumstances challenge the value of the previ-
ously recommended optimal timing of AC (i.e., within 8 weeks). A recent study of the
oncologic outcomes of early AC initiation in colon cancer reported that patients who received
AC within 3 weeks had a better DFS, compared to those who initiated AC beyond 3 weeks.[40]
In the present study of rectal cancer, patients who initiated AC within 20 days had a signifi-
cantly better DFS, compared to those who initiated AC beyond 20 days. Regarding the safety
Table 4. Factors preventing early postoperative chemotherapy.
Total patients (N = 593) Preoperative chemo-radiotherapy (-) (N = 576) Preoperative chemo-radiotherapy (+) (N = 17)
General weakness 241 (40.6%) 237 (41.1%) 4 (23.5%)
Poor compliance 223 (37.6%) 223 (38.7%)
†Anastomosis related complications 66 (11.1%) 56 (9.7%) 10 (47.1%)
Postoperative ileus 23 (3.9%) 23 (4.0%)
‡Infectious complications 13 (2.2%) 13 (2.3%)
ŸCardiovascular complications 6 (1.0%) 5 (0.9%) 1 (5.9%)
Others 21 (3.5%) �19 (5.7%) ��2 (29.4%)
†Anastomosis related complications: anastomotic leakage, anastomotic bleeding, anastomotic ulcer
‡ Infectious complications: wound infection, pneumonia, pseudomembranous colitis perianal abscess, acute pyelonephritis, fever of unknown origin
ŸCardiovascular complications: Ischemic heart disease, atrial fibrillation, pulmonary embolism, cerebral infarction, ischemic colitis
�others for preoperative chemoradiotherapy (-): chyloperitoneum, acute renal failure, femoral neuropathy, acute appendicitis, burn, endometriosis, iatrogenic bowel
injury, neurogenic bladder, aggravated underlying disease (liver cirrhosis, anxiety disorder, gastric ulcer)
��others for preoperative chemoradiotherapy (+): acute renal failure
https://doi.org/10.1371/journal.pone.0228060.t004
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of early AC, patients who started AC within and beyond 20 days did not differ in terms of the
incidence of chemotherapy-induced complications.
The effect of AC on the prognosis of patients treated with preCRT remains debatable.
Although the National Comprehensive Cancer Network and European Society for Medical
Oncology guidelines recommend AC after preCRT and surgery, the Dutch and Norwegian
guidelines do not recommend AC for patients who have received preCRT.[41] Furthermore,
multiple randomized trials have reported a lack of oncologic benefit from AC among patients
who received preCRT.[42–46] In the present study, we observed no significant cut-off point
for AC initiation with regard to oncologic outcomes. We observed only a trend toward better
survival among the patients who received AC within 8 weeks. Because anastomosis-related
complications comprised the major cause of AC delays beyond 8 weeks (47.1%) and as anasto-
motic leakage is a well-known risk factor for cancer recurrence, the observed trend toward bet-
ter oncologic outcomes might indicate a bias toward poor outcomes among patients with
leakage.[47, 48]
Despite the limitations of this retrospective study, the results provide a comprehensive anal-
ysis of the optimal time for AC initiation among patients with rectal cancer, while considering
how preCRT strategies for this type of cancer differ from those for colon cancer. In the era of
MIS, which enables early recovery from surgery, these analyses may provide further insights
into the adjuvant treatment of rectal cancer. Certainly, further studies will be required to estab-
lish the optimal timing of AC and facilitate the management of such patients.
Conclusions
In conclusion, this study suggests that the earlier initiation of AC (i.e., within approximately 3
weeks) was associated with better oncological outcomes, especially DFS, among patients with
rectal cancer. Additionally, among patients who received preCRT, the optimal timing of AC
was unclear and could be attributed to the undetermined role of AC after preCRT or the effects
of complications such as anastomotic leakage.
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